TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05080881

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: physiological measurements: BIOPAC
Description: Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: physiological measurements: Masimo Radical-7
Description: A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: physiological measurements: CoVa Monitoring System 2
Description: This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thoracic impedance
Description: Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
Study: NCT05549479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualified Exercise Professional Support Sessions
Description: Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
Study: NCT05464199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session.
Study: NCT04837001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDY-5301
Description: FDY-5301 will be administered as a single IV bolus injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single bolus injection.
Study: NCT05690542

Intervention type: OTHER
Intervention: blood tests
Description: evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;

Intervention type: OTHER
Intervention: blood tests
Description: evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
Study: NCT05626972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
Study: NCT05591560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole capsule
Description: Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
Study: NCT06024629

Intervention type: DEVICE
Intervention: cOCT and LC-OCT
Description: cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)
Study: NCT04765241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
Study: NCT05501171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DREAMLAND
Description: DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CERENA
Description: CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~1. Education about general wellness.~2. Nutrition.~3. Exercise.~4. Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete.
Study: NCT06390930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Acute Intermittent Hypoxia
Description: During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Acute Intermittent Hypoxia
Description: During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
Study: NCT05438225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated text message reminder
Description: Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
Study: NCT05343117

Intervention type: DRUG
Intervention: Palbociclib based-therapy as initial endocrine therapy
Description: Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)

Intervention type: DRUG
Intervention: Palbociclib based-therapy after chemotherapy
Description: Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
Study: NCT05179044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Sport Rehabilitator knee brace
Description: The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
Study: NCT04840888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Administered orally.
Study: NCT04898842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
Study: NCT04970095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Expander with Differential Opening (EDO)
Description: The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petit Face Mask
Description: The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar
Study: NCT04877574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANI-guided intraoperative analgesia
Description: Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intraoperative analgesia
Description: Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
Study: NCT06624332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI main session
Description: Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI main session
Description: Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI main session
Description: Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI main session
Description: Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI Booster Session
Description: A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-SBI Booster Session
Description: A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 4 weeks of daily automated text messages that reinforce content from the e-SBI main session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 4 weeks of daily automated text messages that reinforce content from the e-SBI main session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 4 weeks of daily automated text messages that reinforce content from the e-SBI main session.
Study: NCT06106035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-fat vegan diet
Description: The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
Study: NCT04684641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose YPT-01
Description: Participants will be randomized to receive the standard dose of phage therapy YPT-01.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive the placebo.
Study: NCT05371119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Training with light load with blood flow restriction (BFR)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Training with light load with blood flow restriction (BFR)
Study: NCT04666922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; 0.9% saline for injection
Study: NCT05142670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental group: task-oriented training individualized by the gravity perception
Description: All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group: visual feedback treatment
Description: Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
Study: NCT05392140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
Description: Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standart care
Description: Standart care
Study: NCT06376643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented reality supportive tool
Description: Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario.~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method (AHA pocket reference card)
Description: Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill.
Study: NCT05964881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrospinous hysteropexy
Description: sacrospinous hysteropexy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacrospinous hysteropexy
Description: sacrospinous hysteropexy
Study: NCT05078528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Mobile Colposcope (MMC)
Description: Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
Study: NCT06044220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
Study: NCT04867785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC